eXoZymes, Inc. (EXOZ)
NASDAQ: EXOZ · Real-Time Price · USD
10.35
+0.03 (0.24%)
Apr 29, 2026, 4:00 PM EDT - Market closed
eXoZymes Employees
eXoZymes had 32 employees as of December 31, 2025. The number of employees increased by 1 or 3.23% compared to the previous year.
Employees
32
Change (1Y)
1
Growth (1Y)
3.23%
Revenue / Employee
n/a
Profits / Employee
-$286,210
Market Cap
87.76M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 32 | 1 | 3.23% |
| Dec 31, 2024 | 31 | 2 | 6.90% |
| Dec 31, 2023 | 29 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Sangamo Therapeutics | 142 |
| Inovio Pharmaceuticals | 112 |
| Adicet Bio | 102 |
| Pelthos Therapeutics | 92 |
| PolyPid | 75 |
| Rani Therapeutics Holdings | 71 |
| NeurAxis | 24 |
EXOZ News
- 19 days ago - eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast - Accesswire
- 4 weeks ago - eXoZymes Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - eXoZymes Provides Fourth Quarter and Full Year 2025 Update - Accesswire
- 5 weeks ago - eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026 - Accesswire
- 6 weeks ago - Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability - Accesswire
- 6 weeks ago - eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium - Accesswire
- 2 months ago - With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation - Accesswire
- 3 months ago - eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run - Accesswire